Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02591199 · ClinicalTrials.gov registry record · Phase 2
Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
A Phase 2 study, sponsored by Urigen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT02591199 is a Phase 2 study that was terminated before completion, run by Urigen. The registered enrollment target is 91 participants.
The verdict
NCT02591199, a Phase 2 study, was terminated before completion, sponsored by Urigen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine Hydrochloride) for the treatment of Interstitial Cystitis/Bladder Pain Syndrome. The study is randomized and double-blinded such that neither the subject nor doctor will know which drug or placebo is received.
Interventions
- DRUG Placebo
- DRUG Lidocaine
- DRUG Heparin
- DRUG URG101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-06-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02591199
The ClinicalTrials.gov registry entry for NCT02591199 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Urigen, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02591199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02591199 about?
NCT02591199 is a clinical study titled "Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome". The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine Hydrochloride) for the treatment of Interstitial Cystitis/Bladder Pain Syndrome. The study is randomized and double-blinded such that nei...
What is the current status of trial NCT02591199?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2015-09. Estimated completion is 2018-06-18.
What interventions are being tested in trial NCT02591199?
The interventions under investigation include: Placebo (DRUG), Lidocaine (DRUG), Heparin (DRUG), URG101 (DRUG).
Who is sponsoring clinical trial NCT02591199?
This trial is sponsored by Urigen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.